Hikma Pharmaceuticals (OTCMKTS:HKMPF) Shares Gap Down – Time to Sell?

Hikma Pharmaceuticals Plc (OTCMKTS:HKMPF) gapped down prior to trading on Monday . The stock had previously closed at $21.6950, but opened at $20.37. Hikma Pharmaceuticals shares last traded at $20.37, with a volume of 450 shares changing hands.

Wall Street Analyst Weigh In

Separately, Citigroup started coverage on Hikma Pharmaceuticals in a report on Thursday. They set a “buy” rating for the company. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold”.

Hikma Pharmaceuticals Price Performance

The company has a debt-to-equity ratio of 0.57, a current ratio of 1.82 and a quick ratio of 1.06. The business’s 50-day moving average price is $19.76 and its two-hundred day moving average price is $19.43.

About Hikma Pharmaceuticals

Hikma Pharmaceuticals is a multinational pharmaceutical company that develops, manufactures and markets a broad range of branded and non-branded generics, specialty injectables and consumer healthcare products. The company’s three core business segments include generic medicines, injectable products and branded generics, serving hospitals, wholesalers and pharmacies worldwide. Its product portfolio spans diverse therapeutic areas such as cardiovascular, oncology, respiratory, pain management and anti-infectives, with an emphasis on injectable solutions for complex hospital treatments.

Founded in 1978 in Amman, Jordan, Hikma has grown through organic expansion and strategic acquisitions to become one of the leading pharmaceutical players in the Middle East, North Africa, Europe and the United States.